Pharmacology

Borderline Personality and Mood Disorders: Comorbidity and Controversy

Volumn , Issue , 2015, Pages 191-206

  Silk, Kenneth R ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944097673     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4939-1314-5_11     Document Type: Chapter

References (89)

1. Deutsch H. Some forms of emotional disturbance and their relationship to schizophrenia. Psychoanal Q. 1942;11:301–21.
2. Hoch P, Polatin P. Pseudoneurotic forms of schizophrenia. Psychiatr Q. 1949;23:248–76.
3. Klein M. Notes on some schizoid mechanisms. Int J Psychoanal. 1946;27:99–110 (Reprinted in J Psychother Prac Res. 1996;5:164–79.).
4. Knight RP. Borderline states. Bull Menninger Clin. 1953;17:139–50.
5. Zilboorg G. Ambulatory schizophrenia. Psychiatry. 1941;4:149–55.
6. Chopra HD, Beatson JA. Psychotic symptoms in borderline personality disorder. Am J Psychiatry. 1986;143:1605–7.
7. Links PS, Steiner M, Mitton J. Characteristics of psychosis in borderline personality disorder. Psychopathology. 1989;22:188–1983.
8. Silk KR, Lohr NE, Westen D, Goodrich S. Psychosis in borderline patients with depression. J Personal Disord. 1989;3:92–100.
9. Frosch J. The psychotic character. Clinical psychiatric considerations. Psychiatr Q. 1964; 38:81–96.
10. Barnow S, Arens EA, Sieswerda S, Dinu-Biringer R, Spitzer C, Lang S. Borderline personality disorder and psychosis: a review. Curr Psychiatry Rep. 2010;12:186–95.
11. Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry. 1986;43:680–6.
12. Leone NF. Response of borderline patients to loxapine and chlorpromazine. J Clin Psychiatry. 1982;43:148–50.
13. Soloff PH, George A, Nathan RS, Schulz PM, Ulrich RF, Perel JM. Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry. 1986;43:691–7.
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.
15. Schmideberg M. The treatment of psychopaths and borderline patients. Am J Psychother. 1947;1:45–70.
16. Kernberg OF. Borderline personality organization. J Am Psychoanal Assoc. 1967;15:641–85.
17. Grinker RR, Werble G, Drye RC. The borderline syndrome. A behavioral study of ego functions. New York: Basic Books; 1968.
18. Gunderson JG, Singer MT. Defining borderline patients, an overview. Am J Psychiatry. 1975;132:1–10.
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1980.
20. Spitzer RL, Endicott J, Gibbon M. Crossing the border into borderline personality and borderline schizophrenia: the development of criteria. Arch Gen Psychiatry. 1979;36:17–24.
21. Akiskal HS, Chen SE, Davis GC, Puzantian VR, Kashgarian M, Bolinger JM. Borderline: an adjective in search of a noun. J Clin Psychiatry. 1985;46:41–8.
22. Akiskal HS, Hirschfeld RMA, Yerevanian BI. The relationship of personality to affective disorders, critical review. Arch Gen Psychiatry. 1983;40:801–10.
23. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personalitydisordered subjects. Arch Gen Psychiatry. 1997;54:1081–8.
24. Montgomery SA, Montgomery D. Pharmacological prevention of suicidal behavior. J Affect Disord. 1982;4:291–8.
25. Rinne T, van den Brink W, Wouters L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry. 2002;159:2048–54.
26. Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, et al. Effect of fl uoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 1995;15:23–9.
27. Soloff PH, George A, Nathan RS, Schulz PM, Cornelius JR, Herring J, et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol. 1989;9:238–46.
28. Soloff PH, Cornelius J, George A, Nathan S, Perel JM, Ulrich RF. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry. 1993;50:377–85.
29. Kramer P. Listening to Prozac. New York: Viking; 1993.
30. Healy D. The antidepressant era. Cambridge: Harvard University Press; 1997.
31. Healy D. Let them eat Prozac. The unhealthy relationship between the pharmaceutical industry and depression. New York: New York University Press; 2004.
32. Parsons B, Quitkin FM, McGrath PJ, Stewart JW, Tricamo E, Ocepek-Welikson K. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull. 1989;25:524–34.
33. Gunderson JG. Borderline personality disorder. Washington, DC: American Psychiatric Press; 1984.
34. Silk KR. The quality of depression in borderline personality disorder and the diagnostic process. J Personal Disord. 2010;24:25–37.
35. Westen D, Moses J, Silk KR, Lohr NE, Cohen R, Segal H. Quality of depressive experience in borderline personality disorders: when depression is not just depression. J Personal Disord. 1992;6:382–93.
36. Gold LJ, Silk KR. Exploring the borderline personality disorder-major affective disorder interface. In: Paris J, editor. Borderline personality disorder: etiology and treatment. Washington, DC: American Psychiatric Press; 1993. p. 39–66.
37. Gunderson JG, Phillips KA. A current view of the interface between borderline personality disorder and depression. Am J Psychiatry. 1991;148:967–75.
38. Gunderson JG, Links P. Borderline personality disorder: a clinical guide. 2nd ed. Washington, DC: American Psychiatric Press; 2008.
39. Main TF. The ailment. Br J Med Psychol. 1960;33:29–31.
40. Linehan MM. Cognitive-behavioral treatment of borderline personality disorder. New York: Guilford Press; 1993.
41. LeQuesne ER, Hersh RG. Disclosure of a diagnosis of borderline personality disorder. J Psychiatr Pract. 2004;10:170–6.
42. American Psychiatric Association. Practice guidelines for the treatment of patients with borderline personality disorder. Am J Psychiatry. 2001;158(10, Suppl):S1–52.
43. Soloff PH. Algorithms for pharmacological treatment of personality dimensions: symptomspecific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation. Bull Menninger Clin. 1998;62:195–214.
44. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifl uoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988;45:111–9.
45. de la Fuente JM, Lotstra F. A trial of carbamazepine in borderline personality disorder. Euro Neuropsychopharmacol. 1994;4:479–86.
46. Gao K, Calabrese JR. Newer treatment studies for bipolar depression. Bipolar Disord. 2005;7 Suppl 5:13–23.
47. Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry. 2005;66 suppl 8:13–21.
48. Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013. Available http://dx.doi.org/10.1371/journal. pmed.1001403.
49. Rothchild AJ, editor. The evidence-based guide to antidepressant medications. Washington, DC: American Psychiatric Publishing; 2012.
50. Rothchild AJ, editor. The evidence-based guide to antipsychotic medications. Washington, DC: American Psychiatric Publishing; 2010.
51. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2002;63:443–6.
52. Hollander E, Allen A, Lopez RP, Bienstock CA, Grossman R, Siever LJ, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry. 2001;62:199–203.
53. Hollander E, Swann AC, Coccaro EF, Jiang P, Smith TB. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry. 2005;162:621–4.
54. Loew TH, Nickel MK, Muehlbacher M, Kaplan P, Nickel C, Kettler C, et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2006;26:61–6.
55. Nickel MK, Nickel C, Kaplan P, Lahmann C, Muehlbacher M, Tritt K, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry. 2005;57:495–9.
56. Nickel MK, Nickel C, Mitterlehner FO, Tritt K, Lahmann C, Leiberich PK. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebocontrolled study. J Clin Psychiatry. 2004;65:1515–9.
57. Tritt K, Nickel C, Lahmann C, Leiberich PK, Rother WK, Loew TH, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo- controlled study. J Psychopharmacol. 2005;19:287–91.
58. Bogenschutz MP, Nurnberg HG. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:104–9.
59. Nickel MK, Muehlbacher M, Nickel C, Kettler C, Gil FP, Bachler E, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006;163:833–8.
60. Pascual JC, Soler J, Puigdemont D, Pérez-Egea R, Tiana T, Alvarez E, et al. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry. 2008;69:603–8.
61. Schulz SC, Zanarini MC, Bateman A, Bohus M, Detke HC, Trzaskoma Q, et al. Olanzapine for the treatment of borderline personality disorder: a variable-dose, 12-week, randomized, double-blind, placebo-controlled study. Br J Psychiatry. 2008;193:485–92.
62. Soler J, Pascual JC, Campins J, Barrachina J, Puigdemont D, Alvarez E, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005;162:1221–4.
63. Simpson EB, Yen S, Costello E, Rosen K, Begin A, Pistorello J, et al. Combined dialectical behavioral therapy and fl uoxetine in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:379–85.
64. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fl uoxetine, olanzapine, and the olanzapine-fl uoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004;65:903–7.
65. Perry JC. Depression in borderline personality disorder: lifetime prevalence at interview and longitudinal course of symptoms. Am J Psychiatry. 1985;142:15–21.
66. Abraham PF, Calabrese JR. Evidenced-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics? J Affect Disord. 2008;111:21–30.
67. Saunders EFH, Silk KR. Personality trait dimensions and the pharmacologic treatment of borderline personality disorder. J Clin Psychopharmacol. 2009;29:461–7.
68. National Institute for Health and Clinical Excellence (NICE). Borderline personality disorder, treatment and management. London: The British Psychological Society and The Royal College of Psychiatrists; 2009. From http://www.nice.org.uk/CG78. Retrieved May 2010.
69. Binks CA, Fenton M, McCarthy L, Lee T, Adams CE, Duggan C. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2006;(1): CD005653.
70. Paris J. Treatment of borderline personality disorder. A guide to evidence-based practice. New York: The Guilford Press; 2008.
71. Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry. 2010;196:4–12.
72. Silk KR, Jibson MD. Personality disorders. In: Rothchild AJ, editor. The evidence-based guide to antidepressant medications. Washington, DC: American Psychiatric Publishing; 2012. p. 139–69.
73. Serban G, Siegel S. Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry. 1984;141:1455–8.
74. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001;62:849–54.
75. Silk KR, Jibson MD. Personality disorders. In: Rothchild AJ, editor. The evidence-based guide to antipsychotic medications. Washington, DC: American Psychiatric Publishing; 2010. p. 101–24.
76. Silk KR, Feurino III L. Psychopharmacology of personality disorders. In: Widiger TA, editor. The Oxford handbook of personality disorders. New York: Oxford University Press; 2012. p. 713–26.
77. Siever LJ, Davis KL. A psychobiological perspective on the personality disorders. Am J Psychiatry. 1991;148:1647–58.
78. Duggan C, Huband N, Smailagic N, Ferriter M, Adams C. The use of pharmacological treatments for people with personality disorder: a systematic review of randomized controlled trials. Pers Ment Health. 2008;2:119–70.
79. Herpertz SC, Zanarini M, Schulz CS, Siever L, Lieb K, Möller HJ, WFSBP Task Force on Personality Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry. 2007;8:212–44.
80. Ingenhoven T, Lafay P, Rinne T, Passchier J, Duivenvoorden H. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry. 2010;71:14–25.
81. Mercer D, Douglass AB, Links PS. Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms. J Personal Disord. 2009;23:156–74.
82. Nosè M, Cipriani A, Biancosino B, Grassi L, Barbui C. Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2006;21:345–53.
83. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes. 2010;17:460–6.
84. Warnock JK, Morris DW. Adverse cutaneous reactions to mood stabilizers. Am J Clin Dermatol. 2003;4:21–30.
85. Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry. 2002;63 Suppl 4:42–55.
86. Gentile S. Neurodevelopmental effects of prenatal exposure to psychotropic medications. Depress Anxiety. 2010;27:675–86.
87. Gunderson JG, Morey LC, Stout RL, Skodol AE, Shea MT, McGlashan TH, et al. Major depressive disorder and borderline personality disorder revisited; longitudinal interactions. J Clin Psychiatry. 2004;65:104901056.
88. Zanarini MC, Stanley B, Black DW, Markowitz JC, Goodman M, Pilkonis P, et al. Methodological considerations treatment trials for persons personality disorder. Ann Clin Psychiatry. 2010;22:75–83.
89. Silk KR. The process of managing medications in patients with borderline personality disorder. J Psychiatr Pract. 2011;17:311–9.